Partner Article
New name for pharma company
PRUDHOE-based pharmaceutical manufacturer The Specials Laboratory has changed its name to PCCA Ltd to reflect the name of its US-based parent company of which it has been a part since 2014.
Although its external company signage will change at its three sites in Low Prudhoe, the unlicensed medicines expert will retain the brand name The Specials Laboratory within the pharmacy, veterinary and hospital markets that it operates in.
Sharon Griffiths, managing director at The Specials Laboratory, said: “At a local level and for all our staff, we will now be known as PCCA to ensure we are consistent with our colleagues in America, Canada and Australia.
“However, given how well-established and respected The Specials Laboratory is amongst our medical and professional customers, this brand name will be retained in the customer sectors in which we operate.”
For over 18 years, The Specials Laboratory has been one of the UK’s leading manufacturers of specials. The award-winning firm works with thousands of community and hospital pharmacists, dispensing doctors and veterinary surgeries across the UK supplying unlicensed medicines within 24 hours to help patients on a daily basis.
For further information about The Specials Laboratory visit: www.specialslab.co.uk or call 0800 028 4925.
This was posted in Bdaily's Members' News section by Richard Crulley .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
The true value of HR in an AI-driven working world
What new business rates guidance means for pubs
Business success starts with people investment
It's time to confront the digital poverty crisis
Why a business exit is no longer all or nothing
Culture is the foundation for sustainable growth
Business must help young people take root in work
Purposeful procurement for long-term growth
Time to rethink outdated views on apprenticeships
The scale-ups rocketing through our fast world
Care about the experience, not just the outcome
The rise of an alternative investor model